Yao Wang

Dr. Yao Wang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2025 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
YWYao Wang
Yao Wang
JGJing Guo
Jing Guo
PZPeiqi Zhang
Peiqi Zhang
QZQing Zhou
Qing Zhou
KPKai Peng
Kai Peng
HLHua Li
Hua Li
Emerging evidence suggests that gut microbiota may mediate the antiseizure effects of the ketogenic diet (KD) in drug-resistant epilepsy (DRE), yet predictive microbial biomarkers remain poorly characterized. This study aimed to investigate gut microbiota signatures associated with therapeutic response to KD in pediatric DRE patients. In this prospective study conducted at Guangdong Sanjiu Brain Hospital, 42 children with DRE (age range: 2-10 years, 22 males and 20 females) received KD therapy. The primary endpoint was assessed at 3 months, with an extended follow-up to 6 months in eligible patients. Fecal samples were collected at baseline and at 1, 2, 3, and 6 months after KD initiation. 16S rRNA gene sequencing was performed to analyze gut microbiota composition. Therapeutic response was defined as ≥50% seizure frequency reduction at 3-month follow-up. The median age at epilepsy onset was 18.50 (8.25-41.50) months, and the median age at KD initiation was 53.50 (41.00-80.75) months. Among 34 patients completing the 3-month follow-up, 16 were responders. Responders showed significantly higher baseline abundances of Lachnoclostridium and Barnesiella. Following three months of KD therapy, responders demonstrated increased levels of Parabacteroides and Akkermansia relative to baseline, whereas these genera remained stable in non-responders. Non-responders exhibited consistently higher abundance of Catenibacterium both at baseline and throughout the intervention period compared to responders. Notably, after one month of KD, responders exhibited significantly elevated levels of Parabacteroides compared to non-responders. Higher baseline abundances of Lachnoclostridium and Barnesiella were identified as potential predictive biomarkers for favorable KD response in pediatric DRE. The dynamic increases in Parabacteroides and Akkermansia during KD intervention further distinguished responders, whereas elevated Catenibacterium levels were associated with poor treatment outcomes, providing preliminary insights for treatment stratification.

11 July 2026 in Epilepsia Open
Verified
Journal Article
Open access
HLHua Li
Hua Li
YWYao Wang
Yao Wang
QGQiang Guo
Qiang Guo
JCJunxi Chen
Junxi Chen
KLKaihui Li
Kaihui Li
JGJing Guo
Jing Guo
Objective: Epileptic spasms (ES) in children carry a high risk of neurodevelopmental delay, yet predictors of long‐term surgical outcome remain incompletely defined. This study aimed to evaluate seizure outcomes following epilepsy surgery and to identify independent prognostic factors for postoperative recurrence. Methods: This retrospective cohort study included 73 patients (47 males, 64%; median age at surgery: 37 months, IQR: 20–55.5) with drug‐resistant ES who underwent resective or ablative surgery at Guangdong Sanjiu Brain Hospital in China between January 2015 and September 2024, with regular follow‐up at least 12 months after epilepsy surgery. Independent predictors of recurrence were identified using multivariate Cox proportional hazards regression, and Kaplan–Meier analysis was performed to compare seizure‐free survival stratified by seizure duration (SD) and residual lesion status. Results: Seizure‐free rates were 75.3% at 1 year and 55.1% at last follow‐up. Mean follow‐up was 61.36 ± 26.10 months (range: 12–132). Among malformation of cortical development (MCD) subtypes, focal cortical dysplasia (FCD) type II demonstrated the highest 5‐year seizure‐free rate (100%), whereas mild MCD (m‐MCD) showed the lowest (33.3%; p = 0.039). On multivariate Cox analysis, residual lesion on postoperative MRI was the strongest independent predictor of recurrence (HR = 5.13; 95% CI: 2.28–11.51; p < 0.001), followed by SD exceeding 36 months (HR = 2.49; 95% CI: 1.17–5.29; p = 0.018). Kaplan–Meier analysis confirmed a twofold difference in 5‐year seizure‐free survival between patients with duration ≤36 versus >36 months (73% vs. 36%; log‐rank p = 0.00069), and significantly better seizure‐free survival in patients without residual lesions (log‐rank p < 0.0001). Significance: Complete lesion resection and early surgical intervention (SD ≤36 months) are independently associated with favorable long‐term seizure outcomes in children with drug‐resistant ES. Pathological subtype, particularly FCD type II, further refines prognostic stratification. These findings support prompt surgical referral and underscore the importance of achieving complete lesion removal to optimize postoperative seizure control. Plain Language Summary: Some children develop a severe form of epilepsy called epileptic spasms that cannot be controlled with medication. In this study of 73 children who had brain surgery for this condition, more than half remained seizure‐free after 5 years. Children who had surgery earlier—before seizures had continued for 3 years—and those in whom the entire abnormal brain tissue was removed did significantly better in the long run. These findings suggest that referring children for surgery sooner rather than later can meaningfully improve their chances of living seizure‐free.

1 July 2026 in Stroke
Verified
Journal Article
Open access
LLLongyan Lu
Longyan Lu
BYBing Yang
Bing Yang
YWYao Wang
Yao Wang
CZChaoli Zhu
Chaoli Zhu
ZLZechao Liu
Zechao Liu
HZHuili Zhu
Huili Zhu
BACKGROUND: Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events in type 2 diabetes. Although body mass index does not seem to modify these effects, whether insulin resistance influences treatment efficacy remains unclear. METHODS: This post hoc analysis of the LAMP trial (Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus; a multicenter, open-label, randomized controlled trial conducted at 27 hospitals in China between June 25, 2019, and December 27, 2023) included patients with minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. Participants were randomized (1:1) to liraglutide plus standard therapy or standard therapy alone. IR was assessed using the homeostasis model assessment of IR, with a cutoff of 2.5 based on prior studies in Asian populations. Treatment-by-IR interactions were evaluated using Cox models. Absolute risk reduction was calculated as the difference in event rates between groups and was based on crude estimates. RESULTS: Among 636 enrolled patients, 510 were included in this analysis (mean age, 65 years; 64.7% male; follow-up, 3 months). A significant interaction between treatment and insulin resistance was observed for both stroke recurrence and composite vascular events ( P for interaction=0.02 for both). Among patients with homeostasis model assessment of IR ≥2.5, liraglutide reduced stroke recurrence (5.8% versus 18.1%; absolute risk reduction, 12.3% [95% CI, 5.6%–19.0%]; number needed to treat=8) and vascular events (5.8% versus 19.2%; absolute risk reduction, 13.4% [95% CI, 6.6%–20.2%]; number needed to treat=8). No significant benefit was observed in those with homeostasis model assessment of IR <2.5. CONCLUSIONS: IR may be an important determinant of the therapeutic efficacy of liraglutide in patients with acute minor ischemic stroke or high-risk transient ischemic attack and type 2 diabetes. IR-based stratification may help optimize the use of glucagon-like peptide-1 receptor agonists in secondary stroke prevention and guide personalized vascular risk management. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03948347.

1 January 2026 in Genetics Research
Verified
Journal Article
Open access
PZPei-Qi Zhang
Pei-Qi Zhang
PWPeng-Yu Wang
Peng-Yu Wang
SZSi-Qi Zhang
Si-Qi Zhang
YDYan Ding
Yan Ding
WLWen-Hui Liu
Wen-Hui Liu
JGJing Guo
Jing Guo
Background: The CCDC22 gene is a key regulator of endosomal trafficking and NF‐κB signaling, and its dysfunction is implicated in a spectrum of X‐linked neurodevelopmental disorders, including Ritscher–Schinzel syndrome 2, intellectual disability, and epilepsy. Despite the identification of CCDC22 variants having increased, a comprehensive biological characterization, including its spatiotemporal expression and functional molecular networks, remains to be systematically delineated. Furthermore, the rarity of CCDC22 variants created a significant challenge in distinguishing their pathogenicity. This study aimed to explore the integration of biological context‐informed and clinical genetic analysis workflows and to perform an exploratory evaluation of prediction algorithms to better optimize the genetic diagnosis process for CCDC22 . Methods: Multilevel biological analysis was performed to evaluate the spatiotemporal expression patterns of CCDC22 across developmental stages. A protein–protein interaction network was constructed to identify key functional modules and pathway enrichments. Additionally, an expert‐classified dataset of CCDC22 missense variants was utilized to conduct an exploratory performance evaluation of twenty prediction algorithms, specifically assessing the effect of filtering out variants observed as population hemizygotes. Result: CCDC22 exhibits distinct spatiotemporal expression dynamics and chromatin accessibility patterns closely associated with neurodevelopmental processes. PPI and functional enrichment analyses highlighted its core involvement in endocytic recycling and vesicle transport. In the exploratory missense variant evaluation, meta‐predictors, notably ClinPred and MetaRNN, demonstrated the highest predictive potential within this limited cohort. After filtering out variants observed as hemizygotes in the gnomAD database, most of the algorithms’ performance improved in distinguishing the pathogenicity of variants and genetic diagnosis. ClinPred, M‐CAP, MetaRNN, and SIFT achieved the highest balanced accuracy (84.6%, 80.8%, 78.7%, and 76.1%, respectively). ClinPred, M‐CAP, and MetaRNN achieved the highest AUC value (> 0.9). Conclusion: This study delineates the spatiotemporal and functional molecular network of CCDC22 in neurodevelopment. A combination of population‐based strategy and prediction enhanced the performance of most algorithms. ClinPred and MetaRNN showed higher predictive potential. This study may provide insights into the evaluation of variants in CCDC22 ‐related diseases.